{"id":"emtricitabine-tenofovir-disoproxil-pill","brandName":"Emtricitabine / Tenofovir Disoproxil Pill","genericName":"Emtricitabine / Tenofovir Disoproxil Pill","companyId":"fundacion-ideaa","companyName":"Fundacion IDEAA","phase":"marketed","status":"active","modality":"Small molecule","aliases":["truvada","dolutegravir"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Emtricitabine/Tenofovir Disoproxil (FTC/TDF) is a fixed-dose combination antiretroviral marketed by Fundacion IDEAA for HIV-1 treatment and PrEP. This dual nucleoside reverse transcriptase inhibitor (NRTI) combination represents a well-established, first-generation backbone therapy with extensive clinical validation across 58 trials and 188 publications. The drug addresses both treatment-naive and prevention populations, with demonstrated efficacy in adults and pediatric patients meeting weight thresholds. As a mature, generic-available therapy, it maintains significant commercial relevance in resource-limited settings and remains foundational in modern antiretroviral regimens despite newer alternatives.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) are antiretroviral agents that work synergistically to suppress HIV-1 replication. Both drugs inhibit reverse transcriptase, the viral enzyme essential for HIV to integrate into host cell DNA. This combination is commonly used as part of highly active antiretroviral therapy (HAART) regimens and is also approved for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in at-risk individuals.","oneSentence":"Emtricitabine and tenofovir disoproxil are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"10-20","effect":"Nausea"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"1-5","effect":"Renal impairment (tenofovir-related)"},{"rate":"5-10","effect":"Bone density loss (tenofovir-related)"},{"rate":"<1","effect":"Lactic acidosis (rare)"}]},"trials":[],"indications":{"approved":[{"name":"HIV-1 infection treatment (as part of combination antiretroviral therapy)"},{"name":"HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}